Sirtuins (SIRTs) are nicotine adenine dinucleotide (+)-dependent histone deacetylases
regulating critical signaling pathways in prokaryotes and eukaryotes, and are involved in …

The centenary of insulin discovery represents an important opportunity to transform diabetes
from a fatal diagnosis into a medically manageable chronic condition. Insulin is a key …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk
manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac …

Obesity and impaired metabolic health are established risk factors for the non-
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …

Kidney fibrosis, characterized by excessive deposition of extracellular matrix (ECM) that
leads to tissue scarring, is the final common outcome of a wide variety of chronic kidney …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …